Nothing Special   »   [go: up one dir, main page]

MX351584B - Formulacion farmaceutica acuosa de tapentadol para administracion oral. - Google Patents

Formulacion farmaceutica acuosa de tapentadol para administracion oral.

Info

Publication number
MX351584B
MX351584B MX2013010101A MX2013010101A MX351584B MX 351584 B MX351584 B MX 351584B MX 2013010101 A MX2013010101 A MX 2013010101A MX 2013010101 A MX2013010101 A MX 2013010101A MX 351584 B MX351584 B MX 351584B
Authority
MX
Mexico
Prior art keywords
oral administration
tapentadol
aqueous pharmaceutical
pharmaceutical formulation
relying
Prior art date
Application number
MX2013010101A
Other languages
English (en)
Other versions
MX2013010101A (es
Inventor
Schiller Marc
Reinhold Ulrich
Wulsten Eva
Feil Ulrich
Karine Sabine Inghelbrecht Katrien
Carolus Roger Embrechts Augusta
Original Assignee
Gruenenthal Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44650617&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX351584(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Gruenenthal Gmbh filed Critical Gruenenthal Gmbh
Publication of MX2013010101A publication Critical patent/MX2013010101A/es
Publication of MX351584B publication Critical patent/MX351584B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/186—Quaternary ammonium compounds, e.g. benzalkonium chloride or cetrimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Inorganic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Rheumatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

La invención se refiere a una composición farmacéutica acuosa que contiene tapentadol o una sal fisiológicamente aceptable del mismo y que está adaptada para la administración oral. La composición tiene una excelente estabilidad de almacenamiento sin depender de la presencia de altas cantidades de conservantes.
MX2013010101A 2011-03-04 2012-03-02 Formulacion farmaceutica acuosa de tapentadol para administracion oral. MX351584B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161449287P 2011-03-04 2011-03-04
EP11003601 2011-05-03
PCT/EP2012/000904 WO2012119727A1 (en) 2011-03-04 2012-03-02 Aqueous pharmaceutical formulation of tapentadol for oral administration

Publications (2)

Publication Number Publication Date
MX2013010101A MX2013010101A (es) 2013-10-01
MX351584B true MX351584B (es) 2017-10-20

Family

ID=44650617

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2017007718A MX369121B (es) 2011-03-04 2012-03-02 Formulacion farmaceutica acuosa de tapentadol para administracion oral.
MX2013010101A MX351584B (es) 2011-03-04 2012-03-02 Formulacion farmaceutica acuosa de tapentadol para administracion oral.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2017007718A MX369121B (es) 2011-03-04 2012-03-02 Formulacion farmaceutica acuosa de tapentadol para administracion oral.

Country Status (23)

Country Link
US (3) US20130022670A1 (es)
EP (4) EP3287123B1 (es)
JP (3) JP6046057B2 (es)
KR (2) KR101946790B1 (es)
CN (2) CN103501773A (es)
AU (2) AU2012224952C1 (es)
BR (1) BR112013022495A2 (es)
CA (1) CA2828631C (es)
CY (2) CY1125100T1 (es)
DK (2) DK3287123T3 (es)
EA (2) EA035750B1 (es)
ES (1) ES2756776T3 (es)
HR (2) HRP20191777T1 (es)
HU (1) HUE046557T2 (es)
IL (2) IL227824B (es)
LT (2) LT2680832T (es)
MX (2) MX369121B (es)
PL (2) PL3287123T3 (es)
PT (2) PT2680832T (es)
RS (2) RS59491B1 (es)
SI (2) SI3287123T1 (es)
WO (1) WO2012119727A1 (es)
ZA (1) ZA201306478B (es)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7776314B2 (en) 2002-06-17 2010-08-17 Grunenthal Gmbh Abuse-proofed dosage system
DE102005005446A1 (de) 2005-02-04 2006-08-10 Grünenthal GmbH Bruchfeste Darreichungsformen mit retardierter Freisetzung
US20070048228A1 (en) 2003-08-06 2007-03-01 Elisabeth Arkenau-Maric Abuse-proofed dosage form
DE10361596A1 (de) 2003-12-24 2005-09-29 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
DE10336400A1 (de) 2003-08-06 2005-03-24 Grünenthal GmbH Gegen Missbrauch gesicherte Darreichungsform
DE102004032049A1 (de) 2004-07-01 2006-01-19 Grünenthal GmbH Gegen Missbrauch gesicherte, orale Darreichungsform
DE102005005449A1 (de) 2005-02-04 2006-08-10 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
WO2009092601A1 (en) 2008-01-25 2009-07-30 Grünenthal GmbH Pharmaceutical dosage form
SI2273983T1 (sl) 2008-05-09 2016-11-30 Gruenenthal Gmbh Postopek za pripravo intermediatne praškaste formulacije in končne trdne odmerne oblike z uporabo stopnje strjevanja z razprševanjem
CA2765971C (en) 2009-07-22 2017-08-22 Gruenenthal Gmbh Hot-melt extruded controlled release dosage form
JP2012533586A (ja) 2009-07-22 2012-12-27 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング 酸化安定化された不正使用防止剤形
PL2611426T3 (pl) 2010-09-02 2014-09-30 Gruenenthal Gmbh Postać dawkowania zawierająca nieorganiczne sole, odporna na zgniatanie
NZ608865A (en) 2010-09-02 2015-03-27 Gruenenthal Chemie Tamper resistant dosage form comprising an anionic polymer
CN103501773A (zh) 2011-03-04 2014-01-08 格吕伦塔尔有限公司 用于口服给予的他喷他多含水药物制剂
EP2753302B1 (en) * 2011-07-20 2018-11-28 Torrent Pharmaceuticals Ltd. Pharmaceutical composition of tapentadol
CA2839126A1 (en) 2011-07-29 2013-02-07 Grunenthal Gmbh Tamper-resistant tablet providing immediate drug release
LT2736495T (lt) 2011-07-29 2017-11-10 Grünenthal GmbH Sugadinimui atspari tabletė, pasižyminti greitu vaisto atpalaidavimu
EP2819656A1 (en) 2012-02-28 2015-01-07 Grünenthal GmbH Tamper-resistant dosage form comprising pharmacologically active compound and anionic polymer
LT2838512T (lt) 2012-04-18 2018-11-12 GrĆ¼nenthal GmbH Pažeidimui atspari ir dozės atpalaidavimo nuokrypiui atspari farmacinė vaisto forma
US10064945B2 (en) 2012-05-11 2018-09-04 Gruenenthal Gmbh Thermoformed, tamper-resistant pharmaceutical dosage form containing zinc
AR096438A1 (es) 2013-05-29 2015-12-30 Gruenenthal Gmbh Forma de dosificación resistente al uso indebido con perfil de liberación bimodal, proceso
EP3003279A1 (en) 2013-05-29 2016-04-13 Grünenthal GmbH Tamper-resistant dosage form containing one or more particles
AU2014289187B2 (en) 2013-07-12 2019-07-11 Grunenthal Gmbh Tamper-resistant dosage form containing ethylene-vinyl acetate polymer
EP2845625A1 (en) * 2013-09-04 2015-03-11 Grünenthal GmbH Tapentadol for use in the treatment of fibromyalgia and chronic fatigue syndrome
CN105934241B (zh) 2013-11-26 2020-06-05 格吕伦塔尔有限公司 通过低温研磨制备粉末状药物组合物
CA2947786A1 (en) * 2014-05-12 2015-11-19 Grunenthal Gmbh Tamper resistant immediate release capsule formulation comprising tapentadol
CA2949422A1 (en) 2014-05-26 2015-12-03 Grunenthal Gmbh Multiparticles safeguarded against ethanolic dose-dumping
HUE042612T2 (hu) * 2015-03-27 2019-07-29 Gruenenthal Gmbh Parenterális alkalmazású stabil Tapentadol készítmény
WO2016170097A1 (en) 2015-04-24 2016-10-27 Grünenthal GmbH Tamper-resistant dosage form with immediate release and resistance against solvent extraction
JP2018526414A (ja) 2015-09-10 2018-09-13 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング 乱用抑止性の即放性製剤を用いた経口過剰摂取に対する保護
CN105997862A (zh) * 2016-07-15 2016-10-12 蓝佳堂生物医药（福建）有限公司 一种口腔溃疡含漱液及其制备方法
KR20190057349A (ko) 2016-09-23 2019-05-28 그뤼넨탈 게엠베하 타펜타돌의 비경구 투여용 안정한 제제
WO2018153947A1 (en) 2017-02-23 2018-08-30 Grünenthal GmbH Tapentadol as local anesthetic
CN108434042A (zh) * 2018-05-31 2018-08-24 武汉新大地环保材料股份有限公司 一种新型日化防腐剂及其制备方法
EP4011369A1 (en) * 2020-12-14 2022-06-15 G.L. Pharma GmbH Aqueous pharmaceutical composition comprising tapentadol tartrate

Family Cites Families (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8334423D0 (en) 1983-12-23 1984-02-01 Sterwin Ag Composition
GB8334422D0 (en) 1983-12-23 1984-02-01 Sterwin Ag Composition
US4775678A (en) 1984-10-01 1988-10-04 Schering Corporation Clotrimazole cream
AU614465B2 (en) 1989-04-05 1991-08-29 Yissum Research Development Company Of The Hebrew University Of Jerusalem Medicinal emulsions
DE4426245A1 (de) 1994-07-23 1996-02-22 Gruenenthal Gmbh 1-Phenyl-3-dimethylamino-propanverbindungen mit pharmakologischer Wirkung
US6183758B1 (en) 1998-01-29 2001-02-06 Highland Laboratories, Inc. Phytochemicals, nutrients & medication absorption &/or treatment
US6211169B1 (en) 1999-09-29 2001-04-03 Aesgen, Inc. Stable calcitriol solution for packaging into vials
FR2809619B1 (fr) 2000-06-06 2004-09-24 Pharmatop Nouvelles formulations aqueuses de principes actifs sensibles a l'oxydation et leur procede d'obtention
US6594193B2 (en) * 2000-06-22 2003-07-15 Progressent Technologies, Inc. Charge pump for negative differential resistance transistor
US6399087B1 (en) 2000-12-20 2002-06-04 Amphastar Pharmaceuticals, Inc. Propofol formulation with enhanced microbial inhibition
US20050176790A1 (en) 2001-02-28 2005-08-11 Johannes Bartholomaus Pharmaceutical salts
DE10109763A1 (de) 2001-02-28 2002-09-05 Gruenenthal Gmbh Pharmazeutische Salze
DE10112325A1 (de) 2001-03-13 2002-10-02 Fresenius Kabi De Gmbh Lagerstabile Fertiginfusionslösungen des Paracetamols
JP4905616B2 (ja) 2001-04-19 2012-03-28 ライオン株式会社 ソフトコンタクトレンズ用点眼剤
US6638981B2 (en) 2001-08-17 2003-10-28 Epicept Corporation Topical compositions and methods for treating pain
PE20030527A1 (es) 2001-10-24 2003-07-26 Gruenenthal Chemie Formulacion farmaceutica con liberacion retardada que contiene 3-(3-dimetilamino-1-etil-2-metil-propil) fenol o una sal farmaceuticamente aceptable del mismo y tabletas para administracion oral que la contienen
FR2832063B1 (fr) 2001-11-15 2004-08-27 Aguettant Lab Procede de production de solutions stables de substances phenoliques et les solutions en resultant
WO2003077897A1 (en) * 2002-03-15 2003-09-25 Cypress Bioscience, Inc. Ne and 5-ht reuptake inhibitors for treating visceral pain syndromes
US20030191187A1 (en) 2002-04-01 2003-10-09 Lee Fang Yu Injectable pharmaceutical composition containing a non-steroidal anti-inflammatory drug and method for preparing the same
US20040101563A1 (en) * 2002-07-18 2004-05-27 Kundu Subhas C. Storage stable antihistaminic syrup formulations
CA2498410A1 (en) * 2002-09-13 2004-03-25 Cydex, Inc. Capsules containing aqueous fill compositions stabilized with derivatized cyclodextrin
US6888993B2 (en) 2002-11-27 2005-05-03 Corning Incorporated Dispersion compensating optical fiber for SMF and transmission link including same
ITMI20022748A1 (it) 2002-12-23 2004-06-24 Eurand Int Dispersioni solide stabilizzate di farmaco in un carrier organico e procedimento per la loro preparazione.
DK1599222T3 (da) 2003-01-08 2009-04-27 Novartis Vaccines & Diagnostic Stabiliserede vandige pr parater omfattende v vsfaktorvej-inhibitor (TFPI) eller v vsfaktorvej-inhibitorvariant
US20040180915A1 (en) 2003-03-14 2004-09-16 Xanodyne Pharmacal, Inc. Methadone-containing compositions for parenteral administration and method of use thereof
US20060111382A1 (en) * 2004-05-17 2006-05-25 Pharmacofore, Inc. Compositions and methods for treating or preventing pain
ATE368639T1 (de) 2004-06-28 2007-08-15 Gruenenthal Gmbh Kristalline formen von (-)-(1r,2r)-3-(3- dimethylamino-1-ethyl-2-methylpropyl)-phenol hydrochlorid
KR101204657B1 (ko) 2004-07-01 2012-11-27 그뤼넨탈 게엠베하 (1r,2r)-3-(3-디메틸아미노-1-에틸-2-메틸-프로필)-페놀을 함유하는 남용 방지 경구 투여 제형
DE102004032103A1 (de) 2004-07-01 2006-01-19 Grünenthal GmbH Gegen Missbrauch gesicherte, orale Darreichungsform
EP1893190A4 (en) 2005-04-28 2010-07-28 Theraquest Biosciences Llc METHODS AND COMPOSITIONS FOR TREATING PAIN
TWI329334B (en) 2005-12-02 2010-08-21 Chung Shan Inst Of Science Manufacture method of electromagnetic interference layer for the plasma display panel
US20070166336A1 (en) * 2005-12-13 2007-07-19 David Delmarre Stable and palatable oral liquid sumatriptan compositions
US8176534B2 (en) 2005-12-30 2012-05-08 General Instrument Corporation Method and apparatus for provisioning a device to access digital rights management (DRM) services in a universal plug and play (UPnP) network
WO2007127158A2 (en) 2006-04-25 2007-11-08 Croda, Inc Modification of percutaneous absorption of topically active materials
ATE502629T1 (de) 2006-04-28 2011-04-15 Gruenenthal Gmbh Pharmazeutische kombination mit 3- (3- dimethylamino-1-ethyl-2-methyl-propyl) phenol und einem nsar
CN101431990B (zh) 2006-04-28 2011-08-03 格吕伦塔尔有限公司 包含3-（3-二甲基氨基-1-乙基-2-甲基-丙基）-酚和对乙酰氨基酚的药物结合
TWI401237B (zh) * 2006-07-24 2013-07-11 ３-〔（１ｒ，２ｒ）-３-（二甲基氨基）-１-乙基-２-甲基丙基〕酚之製備
JP5208933B2 (ja) 2006-07-24 2013-06-12 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ （２ｒ，３ｒ）−３−（３−メトキシフェニル）−ｎ，ｎ，２−トリメチルペンタナミンの製造
EP1905440A1 (de) 2006-09-06 2008-04-02 Boehringer Ingelheim Pharma GmbH & Co. KG Verwendung einer pharmazeutischen Zusammensetzung enthaltend ein Anticholinergikum zur Abtötung von Mikroorganismen und zur Behandlung von Atemwegsinfektionen
TWI394564B (zh) 2006-09-21 2013-05-01 Alcon Res Ltd 自行保存型水性藥學組成物
DE102007012165A1 (de) 2007-03-12 2008-09-18 Grünenthal GmbH Verwendung von 1-Phenyl-3-dimethylamino-propanverbindungen zur Therapie des Neuropathieschmerzes
JP2008266168A (ja) 2007-04-18 2008-11-06 Teika Seiyaku Kk 眼科用剤
EP1985292A1 (en) 2007-04-23 2008-10-29 Grünenthal GmbH Titration of tapentadol
EP1992334A1 (en) 2007-05-08 2008-11-19 Docpharma NV/SA Storage-stable formulation of oxidation-sensitive phenolic drug, especially paracetamol, comprises aqueous drug solution deoxygenated by a temperature-controlled manufacturing process of the formulation
AU2008321353A1 (en) * 2007-11-16 2009-05-22 The Arizona Board Of Regents On Behalf Of The University Of Arizona Methods for treating visceral pain
LT2596784T (lt) 2007-11-23 2017-03-27 Grünenthal GmbH Tapentadolio kompozicijos
AU2008335360A1 (en) * 2007-12-06 2009-06-18 Pain Therapeutics, Inc. Micronized opioid compositions, formulations and dosage forms and methods of making same
WO2009092601A1 (en) 2008-01-25 2009-07-30 Grünenthal GmbH Pharmaceutical dosage form
EP2280688B1 (en) 2008-04-08 2012-01-25 Acino Pharma AG Aqueous pharmaceutical formulation
DK2352494T3 (da) * 2008-10-30 2019-10-28 Gruenenthal Gmbh Nye og potente tapentadoldoseringsformer
SG172833A1 (en) * 2009-01-09 2011-08-29 Panacea Biotec Ltd Dual release pharmaceutical suspension
WO2010100477A2 (en) * 2009-03-03 2010-09-10 Shire Llc Amino acid and peptide carbamate prodrugs of tapentadol and uses thereof
EP2246044A1 (en) 2009-04-21 2010-11-03 Pierre Fabre Dermo-Cosmétique Paediatric solutions comprising a beta-blocker
US20100272815A1 (en) * 2009-04-28 2010-10-28 Actavis Group Ptc Ehf Amorphous form of tapentadol hydrochloride
US8551949B2 (en) 2009-07-27 2013-10-08 Nocicepta Llc Methods for treatment of pain
WO2011016487A1 (ja) * 2009-08-05 2011-02-10 ナガセ医薬品株式会社 インジゴカルミン製剤
CN102711726A (zh) 2009-12-10 2012-10-03 特克尼梅德医疗技术股份公司 用于制备扑热息痛稳定液体制剂的方法和组合物
US20110190267A1 (en) 2010-01-05 2011-08-04 Shire Pharmaceuticals, Inc. Prodrugs of opioids and uses thereof
TWI507193B (zh) 2010-03-30 2015-11-11 Phosphagenics Ltd 經皮輸送貼劑
GB201006200D0 (en) * 2010-04-14 2010-06-02 Ayanda As Composition
CN101948397A (zh) 2010-09-07 2011-01-19 天津泰普药品科技发展有限公司 镇痛药他喷他多重要中间体的制备方法
US20120270848A1 (en) 2010-10-22 2012-10-25 Galleon Pharmaceuticals, Inc. Novel Compositions and Therapeutic Methods Using Same
CN103501773A (zh) 2011-03-04 2014-01-08 格吕伦塔尔有限公司 用于口服给予的他喷他多含水药物制剂
AU2012224953C1 (en) 2011-03-04 2017-07-13 Grünenthal GmbH Parenteral administration of tapentadol
JP6027549B2 (ja) 2011-03-04 2016-11-16 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング タペンタドールを含む半固形の水性医薬組成物
US20150073000A1 (en) 2012-03-27 2015-03-12 Fresenius Kabi Oncology Limited Stable ready-to-use pharmaceutical composition of pemetrexed
CN103159633B (zh) 2012-07-06 2015-08-12 江苏恩华药业股份有限公司 他喷他多的制备方法及用于制备他喷他多的化合物
GB201309654D0 (en) 2013-05-30 2013-07-17 Euro Celtique Sa Method
CN103735500B (zh) 2014-01-28 2016-01-20 江苏华泽医药科技有限公司 盐酸他喷他多注射液及其制备方法
HUE042612T2 (hu) 2015-03-27 2019-07-29 Gruenenthal Gmbh Parenterális alkalmazású stabil Tapentadol készítmény

Also Published As

Publication number Publication date
HUE046557T2 (hu) 2020-03-30
EP3287123B1 (en) 2020-04-22
LT2680832T (lt) 2019-10-25
SI3287123T1 (sl) 2020-07-31
MX2013010101A (es) 2013-10-01
DK2680832T3 (da) 2019-10-14
EP2680832A1 (en) 2014-01-08
KR102051800B1 (ko) 2019-12-04
RS59491B1 (sr) 2019-12-31
JP6046057B2 (ja) 2016-12-14
MX369121B (es) 2019-10-30
SI2680832T1 (sl) 2019-11-29
HRP20191777T1 (hr) 2020-01-24
US20160220516A1 (en) 2016-08-04
ES2756776T3 (es) 2020-04-27
EP2680832B1 (en) 2019-09-04
AU2016273858B2 (en) 2018-04-26
US20200054584A1 (en) 2020-02-20
IL254854B (en) 2022-03-01
CY1125100T1 (el) 2022-07-22
EA201300989A1 (ru) 2014-02-28
HRP20200898T1 (hr) 2020-10-02
WO2012119727A1 (en) 2012-09-13
IL227824A0 (en) 2013-09-30
CY1123023T1 (el) 2021-10-29
CA2828631A1 (en) 2012-09-13
JP6735790B2 (ja) 2020-08-05
AU2016273858A1 (en) 2017-01-12
KR20140017586A (ko) 2014-02-11
EP3287123A1 (en) 2018-02-28
JP2017061521A (ja) 2017-03-30
US20130022670A1 (en) 2013-01-24
EA035750B1 (ru) 2020-08-05
US11547678B2 (en) 2023-01-10
RS60267B1 (sr) 2020-06-30
BR112013022495A2 (pt) 2016-12-06
LT3287123T (lt) 2020-06-10
CN107308108A (zh) 2017-11-03
AU2012224952A1 (en) 2013-09-19
AU2012224952C1 (en) 2017-03-09
PT3287123T (pt) 2020-05-22
PT2680832T (pt) 2019-10-28
ZA201306478B (en) 2014-05-28
CN103501773A (zh) 2014-01-08
KR20190017056A (ko) 2019-02-19
PL2680832T3 (pl) 2020-03-31
EA027290B1 (ru) 2017-07-31
CA2828631C (en) 2019-10-15
EP3685827A1 (en) 2020-07-29
JP2014506899A (ja) 2014-03-20
IL227824B (en) 2018-04-30
EP3597182A1 (en) 2020-01-22
EA201692443A1 (ru) 2017-08-31
PL3287123T3 (pl) 2020-11-02
JP6437984B2 (ja) 2018-12-12
JP2018162271A (ja) 2018-10-18
DK3287123T3 (da) 2020-06-02
AU2012224952B2 (en) 2016-09-22
IL254854A0 (en) 2017-12-31
KR101946790B1 (ko) 2019-02-13

Similar Documents

Publication Publication Date Title
MX351584B (es) Formulacion farmaceutica acuosa de tapentadol para administracion oral.
PH12017500281A1 (en) Pyrrolopyrimidine compounds used as tlr7 agonist
MX348823B (es) Formulaciones estables de linaclotida.
UA106636C2 (uk) Морфолінотіазоли як позитивні алостеричні модулятори альфа 7
TN2012000392A1 (en) Oral formulations and lipophilic salts of methylnaltrexone
BR112015000229A2 (pt) formulações aquosas estáveis de etanercept
CY1115556T1 (el) Φαρμακευτικη συνθεση για χορηγηση απο το στομα η οποια περιλαμβανει ετεξιλικη δαβιγατρανη
MX340147B (es) Composiciones farmacéuticas y nutracéuticas del ácido abscísico.
EA033171B1 (ru) Полутвёрдая фармацевтическая композиция на водной основе, содержащая тапентадол
MX347105B (es) Composiciones farmaceuticas que comprenden hidromorfona y naloxona.
MY168212A (en) A new therapeutical composition containing apomorphine as active ingredient
PH12015500823A1 (en) Modified release formulations for oprozomib
MX2016001422A (es) Composicion farmaceutica de fingolimod.
EP2871187A4 (en) NOVEL COMPOUND OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME AS ACTIVE INGREDIENT
MX357704B (es) Composiciones farmaceuticas topicas de tipo emulsion aceite en agua que contienen un retinoide.
GR1008228B (el) Φαρμακευτικο σκευασμα περιεχον ενα διπλο αναστολεα επαναπροσληψης και μεθοδος για την παρασκευη αυτου
MX363558B (es) Composiciones farmaceuticas que comprenden flurbiprofeno.
EA201590732A1 (ru) Диспергируемая таблетка
EA201500366A1 (ru) Применение 1-адамантилетилокси-3-морфолино-2-пропанола или его фармацевтически приемлемых солей в фармацевтических композициях в качестве нейроретинопротектора
WO2012108794A3 (ru) Производные 1,2,4-триазол-з-илтиогликолевой кислоты для применения в терапии
GR1007907B (el) Φαρμακευτικο σκευασμα περιεχον ενα φαινοκαρβαμικο αναστολεα της ακετυλχοληνεστερασης
IN2014MU01179A (es)
MX2013003022A (es) Composiciones farmaceuticas de montelukast y levocetirizina.
IN2013MU01330A (es)
WO2014141298A3 (en) Stable pharmaceutical composition of fingolimod

Legal Events

Date Code Title Description
FG Grant or registration